A Phase 1/2 interventional study of EC5026 oral tablet and Placebo in Parkinson's Disease (PD), sponsored by EicOsis Human Health Inc.. Recruiting at 1 site in United States. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by EicOsis Human Health Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if the oral drug candidate EC5026 is safe and targets the correct pathways to treat Parkinson's Disease in adults. It will also learn about the levels of drug that are achieved in blood and in the fluid surrounding the brain (spinal fluid). The main questions it aims to answer are:
In addition, although it is not one of the primary aims of the study, this clinical trial will also explore if oral administration of EC5026 improves the symptoms of Parkinson's Disease.
Researchers will compare EC5026 to a placebo (a look-alike substance that contains no drug).
Participants will:
This is a double-blind, randomized, placebo-controlled Phase 1b multiple ascending dose (MAD) study to be conducted in adult male and female participants with Parkinson's Disease. The aim is to evaluate the safety, pharmacokinetics (PK), target engagement, and exploratory efficacy, of 2 ascending dose regimens of oral EC5026 in participants with Parkinson's Disease.
The study drug, EC5026, is an orally bioavailable inhibitor of an enzyme, soluble epoxide hydrolase (sEH), that is being developed as a first-in-class anti-inflammatory agent. Inhibiting sEH maintains concentrations of bioavailable polyunsaturated fatty acid epoxides, known as epoxy fatty acids (EpFAs). EpFAs are potent, endogenous fatty acids that are highly produced in areas of damaged and inflamed tissue but are rapidly metabolized by sEH in vivo. Therefore, selective inhibition of sEH prolongs and enhances the anti-inflammatory activity of EpFAs. Several studies have identified the sEH enzyme as a potential therapeutic target for modulating neuroinflammatory responses in PD.
EicOsis Human Health Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with any of the following blood values at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once-daily, oral dose of 2 mg of EC5026 for 28 consecutive days
Drug: EC5026 oral tablet
Once-daily, oral dose of 4 mg of EC5026 for 28 consecutive days
Drug: EC5026 oral tablet
Once-daily, matching placebo for each dose cohort, orally for 28 consecutive days.
Drug: Placebo
Oral soluble epoxide hydrolase inhibitor
Matching oral placebo
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAE) [Safety and Tolerability]
All AEs reported or observed during the study will be recorded on the electronic case report forms (eCRF). Information to be collected includes drug treatment, type of event, time of onset, dosage, investigator-specified assessment of severity and relationship to study drug, time of resolution of the event, seriousness, any required treatment or evaluations, and outcome. Any AEs resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent medications, or progression of disease states must also be reported. All AEs will be followed until they are resolved, stable, or judged by the investigator to be not clinically significant. The Medical Dictionary for Regulatory Activities will be used to code all AEs.
Time frame: 56 days
Effects of 2 ascending multiple dose regimens of EC5026 versus placebo on plasma and cerebrospinal fluid levels of EC5026
Standard validated EC5026 measurement platform will be used
Time frame: 56 days
Effects of 2 ascending multiple dose regimens of EC5026 versus placebo on plasma and cerebrospinal fluid target engagement biomarkers.
Target engagement biomarkers will include changes from baseline of a validated analytical platform of inflammatory cytokines, neurological markers including target inflammatory genes tied to the mechanism of action, ER-stress response genes, and Parkinson's Disease specific biomarkers (including alpha-synuclein, Abeta42, pTau-181, GFAP, and Neurofilament Light).
Time frame: 56 days.
Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score (Day 14)
Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score on Day 14. The Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) is a comprehensive tool used to assess Parkinson's Disease (PD) symptoms and severity through a series of questions rated by clinicians, patients, and caregivers. Scores are on a 0-4 scale, with higher scores indicating a greater impact of PD symptoms. The scale is divided into four parts, covering non-motor and motor experiences of daily living, motor examination, and motor complications.
Time frame: Day 14
Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score (Day 28)
Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score on Day 28. The Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) is a comprehensive tool used to assess Parkinson's Disease (PD) symptoms and severity through a series of questions rated by clinicians, patients, and caregivers. Scores are on a 0-4 scale, with higher scores indicating a greater impact of PD symptoms. The scale is divided into four parts, covering non-motor and motor experiences of daily living, motor examination, and motor complications.
Time frame: Day 28
Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score (Day 56 - End of Study)
Change from Baseline in Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Score on Day 56 or end of study visit. The Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) is a comprehensive tool used to assess Parkinson's Disease (PD) symptoms and severity through a series of questions rated by clinicians, patients, and caregivers. Scores are on a 0-4 scale, with higher scores indicating a greater impact of PD symptoms. The scale is divided into four parts, covering non-motor and motor experiences of daily living, motor examination, and motor complications.
Time frame: Day 56
Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) (Day 14)
Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) on Day 14. The Movement Disorders Society (MDS) Non-Motor Symptom Scale (MDS-NMS) is evaluates 52 items, grouped according to clinical content into 13 domains. Items are scored for frequency (from 0 \[never\] to 4 \[majority of time\]) and severity (from 0 \[not present\] to 4 \[severe\]), which are multiplied to generate the item total score. Scores for each domain and the total rating scale (maximum, 832 points) are calculated by summing the corresponding items. The scale provides a total score representing the non-motor burden. Higher scores imply a higher non-motor symptom burden.
Time frame: Day 14
Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) (Day 28)
Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) on Day 28. The Movement Disorders Society (MDS) Non-Motor Symptom Scale (MDS-NMS) is evaluates 52 items, grouped according to clinical content into 13 domains. Items are scored for frequency (from 0 \[never\] to 4 \[majority of time\]) and severity (from 0 \[not present\] to 4 \[severe\]), which are multiplied to generate the item total score. Scores for each domain and the total rating scale (maximum, 832 points) are calculated by summing the corresponding items. The scale provides a total score representing the non-motor burden. Higher scores imply a higher non-motor symptom burden.
Time frame: Day 28
Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) (Day 56 - End of Study)
Change from Baseline in Movement Disorders Society Non-Motor Symptom Scale (NMS) on Day 56 or end of study visit. The Movement Disorders Society (MDS) Non-Motor Symptom Scale (MDS-NMS) is evaluates 52 items, grouped according to clinical content into 13 domains. Items are scored for frequency (from 0 \[never\] to 4 \[majority of time\]) and severity (from 0 \[not present\] to 4 \[severe\]), which are multiplied to generate the item total score. Scores for each domain and the total rating scale (maximum, 832 points) are calculated by summing the corresponding items. The scale provides a total score representing the non-motor burden. Higher scores imply a higher non-motor symptom burden.
Time frame: Day 56
Change from Baseline in Time to Complete Time Up and Go (TUG) Test (Day 14)
Change from Baseline in Time to Complete Time Up and Go (TUG) Test on Day 14. The Time Up and Go (TUG) test time varies, but healthy older adults typically complete it in under 10 seconds. A score of 12 seconds or more indicates increased fall risk, with a threshold of 13.5 seconds often used for community-dwelling adults. Scores of 20 seconds or more signal poor physical performance and higher fall risk, while very frail individuals might take two minutes or more to finish.
Time frame: Day 14
Change from Baseline in Time to Complete Time Up and Go (TUG) Test (Day 28)
Change from Baseline in Time to Complete Time Up and Go (TUG) Test on Day 28. The Time Up and Go (TUG) test time varies, but healthy older adults typically complete it in under 10 seconds. A score of 12 seconds or more indicates increased fall risk, with a threshold of 13.5 seconds often used for community-dwelling adults. Scores of 20 seconds or more signal poor physical performance and higher fall risk, while very frail individuals might take two minutes or more to finish.
Time frame: Day 28
Change from Baseline in Time to Complete Time Up and Go (TUG) Test (Day 56 - End of Study)
Change from Baseline in Time to Complete Time Up and Go (TUG) Test on Day 56 or end of study visit. The Time Up and Go (TUG) test time varies, but healthy older adults typically complete it in under 10 seconds. A score of 12 seconds or more indicates increased fall risk, with a threshold of 13.5 seconds often used for community-dwelling adults. Scores of 20 seconds or more signal poor physical performance and higher fall risk, while very frail individuals might take two minutes or more to finish.
Time frame: Day 56
Change from Baseline in Clinical Global Impression (CGI) Scale (Day 14)
Change from Baseline in Clinical Global Impression (CGI) Scale on Day 14. The CGI was developed for use in NIMH-sponsored clinical trials to provide a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. The CGI has two components-the CGI-Severity, which rates illness severity (on a scale from 1 to 7), and the CGI-Improvement, which rates change from the initiation (baseline) of treatment (on a similar 7-point scale). Higher scores in the 7-point scale for each of the components implies worse severity (CGI-S) or a change to worse from baseline (CGI-I).
Time frame: Day 14
Change from Baseline in Clinical Global Impression (CGI) Scale (Day 28)
Change from Baseline in Clinical Global Impression (CGI) Scale on Day 28. The CGI was developed for use in NIMH-sponsored clinical trials to provide a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. The CGI has two components-the CGI-Severity, which rates illness severity (on a scale from 1 to 7), and the CGI-Improvement, which rates change from the initiation (baseline) of treatment (on a similar 7-point scale). Higher scores in the 7-point scale for each of the components implies worse severity (CGI-S) or a change to worse from baseline (CGI-I).
Time frame: Day 28
Change from Baseline in Clinical Global Impression (CGI) Scale (Day 56 - End of Study)
Change from Baseline in Clinical Global Impression (CGI) Scale on Day 56. The CGI was developed for use in NIMH-sponsored clinical trials to provide a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. The CGI has two components-the CGI-Severity, which rates illness severity (on a scale from 1 to 7), and the CGI-Improvement, which rates change from the initiation (baseline) of treatment (on a similar 7-point scale). Higher scores in the 7-point scale for each of the components implies worse severity (CGI-S) or a change to worse from baseline (CGI-I).
Time frame: Day 56
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score (Day 14)
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score on Day 14. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month. Specifically, it assesses how often patients experience difficulties across the 8 quality of life dimensions of functioning and well-being. It uses a 5-point scale for each of the 39 questions as follows: 0 = Never; 1 = Rarely; 2 = Sometimes; 3 = Often; and 4 = Always. The minimum score is 0 that means good health, while the maximum score is 100 that is bad health; a higher score indicates a lower quality of life.
Time frame: Day 14
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score (Day 28)
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score on Day 28. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month. Specifically, it assesses how often patients experience difficulties across the 8 quality of life dimensions of functioning and well-being. It uses a 5-point scale for each of the 39 questions as follows: 0 = Never; 1 = Rarely; 2 = Sometimes; 3 = Often; and 4 = Always. The minimum score is 0 that means good health, while the maximum score is 100 that is bad health; a higher score indicates a lower quality of life.
Time frame: Day 28
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score (Day 56 - End of Study)
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) total score on Day 56. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month. Specifically, it assesses how often patients experience difficulties across the 8 quality of life dimensions of functioning and well-being. It uses a 5-point scale for each of the 39 questions as follows: 0 = Never; 1 = Rarely; 2 = Sometimes; 3 = Often; and 4 = Always. The minimum score is 0 that means good health, while the maximum score is 100 that is bad health; a higher score indicates a lower quality of life.
Time frame: Day 56
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EC5026
EicOsis Human Health Inc.